Drug Update · Neurology

FDA Approves Atogepant for Episodic Migraine: 1.7‑Day MMD Drop (ADVANCE)

July 18, 2026

Primary endpoint difference (60 mg vs placebo)

-1.7 days (mean change −4.2 vs −2.5 days; 95% CI, −2.3 to −1.2; P<0.001) [1]

≥50% responder rate (60 mg)

61% vs 29% placebo (difference 32%; P<0.001) [1]

Common adverse events

Constipation 6.9–7.7%; Nausea 4.4–6.1%; Fatigue/somnolence listed in label [1][11]

Approval date

2021-09-28 (FDA) [12]

Approved doses (episodic migraine)

10 mg, 30 mg, or 60 mg once daily [9][11]

Clinical Perspective

Neurologists and headache specialists now have an oral CGRP receptor antagonist approved specifically for preventive treatment of episodic migraine in adults with demonstrated reductions in monthly migraine days across doses in the ADVANCE program. The label provides three once‑daily dose options (10 mg, 30 mg, 60 mg) for episodic migraine and includes guidance on dose modification with interacting drugs and in severe renal impairment ^[2]^[3]. Clinicians should weigh efficacy versus tolerability (notably constipation and nausea rates and postmarketing vascular reports) and monitor liver tests as noted in the prescribing information.

Dr. Vikram Patel · Neurology

The FDA approved atogepant (Qulipta) for the preventive treatment of episodic migraine in adults on 2021-09-28 based on the phase 3 ADVANCE trial, which showed a mean reduction in monthly migraine days of 1.7 days with atogepant 60 mg versus placebo over 12 weeks (mean change −4.2 vs −2.5 days; difference −1.7 days; 95% CI, −2.3 to −1.2; P<0.001) ^[1]^[4]. Clinicians should consult current prescribing information for full dosing guidance. The approval and dosing recommendations appear in the approved prescribing information and highlights ^[2]^[3]^[4].

Clinical Context

Atogepant is an oral small‑molecule calcitonin gene‑related peptide (CGRP) receptor antagonist developed and marketed by AbbVie for migraine prevention. The ADVANCE trial program evaluated once‑daily oral atogepant in adults with 4 to 14 migraine days per month and provided the pivotal efficacy data used in the approval ^[1]^[2]^[3]. The approved label lists recommended once‑daily doses of 10 mg, 30 mg, or 60 mg for episodic migraine and a 60 mg dose for chronic migraine; dosing modifications for interacting drugs and for renal impairment are specified in the prescribing information ^[2]^[3]. Clinicians should consult current prescribing information for complete dosing guidance.

Key Findings

The ADVANCE trial showed that atogepant 60 mg once daily reduced mean monthly migraine days by 1.7 days versus placebo across the 12‑week treatment period (mean change −4.2 days with 60 mg vs −2.5 days with placebo; difference −1.7 days; 95% CI, −2.3 to −1.2; P<0.001) ^[1].
Clinicians should consult current prescribing information for full dosing guidance.
Atogepant 10 mg and 30 mg also reduced monthly migraine days versus placebo: mean changes across 12 weeks were −3.7 days (10 mg) and −3.9 days (30 mg) versus −2.5 days with placebo; differences versus placebo were −1.2 days (95% CI, −1.8 to −0.6) and −1.4 days (95% CI, −1.9 to −0.8), respectively (P<0.001 for each comparison) ^[1].
Secondary efficacy outcomes in ADVANCE favored atogepant across doses, including mean monthly headache days and monthly acute medication use days (mean differences versus placebo ranged from −1.3 to −1.5 days for acute medication use) ^[1].
Responder rates (≥50% reduction in mean monthly migraine days averaged over 3 months) were 56% with 10 mg, 59% with 30 mg, and 61% with 60 mg versus 29% with placebo; differences versus placebo were 27%, 30%, and 32%, respectively (P<0.001 for each) ^[1].

Safety & Tolerability

The most common adverse events reported in ADVANCE included constipation and nausea; constipation occurred in 6.9% to 7.7% across atogepant doses and nausea occurred in 4.4% to 6.1% across atogepant doses in the trial ^[1].
The approved prescribing information and highlights also list fatigue/somnolence among the most common adverse reactions and note hypersensitivity reactions including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema in postmarketing reports ^[2]^[3].
Liver enzyme elevations were observed: across the pivotal studies the rate of transaminase elevations >3 times the upper limit of normal was reported as 0.9% with atogepant and 1.2% with placebo; cases temporally associated with treatment were asymptomatic and resolved within 8 weeks of discontinuation in the controlled program ^[3].
Postmarketing warnings in the label include reports of new‑onset or worsening hypertension and Raynaud’s phenomenon with CGRP antagonists, including atogepant; cases have included serious outcomes in the postmarketing setting ^[3].
Serious adverse events in ADVANCE included one case each of asthma and optic neuritis reported in the 10‑mg atogepant group ^[1].

Study Design

ADVANCE was a phase 3, randomized, double‑blind trial that enrolled adults with 4 to 14 migraine days per month and assigned participants in a 1:1:1:1 ratio to once‑daily atogepant 10 mg, 30 mg, 60 mg, or placebo for 12 weeks; the primary endpoint was the change from baseline in mean monthly migraine days across 12 weeks ^[1]. Clinicians should consult current prescribing information for full dosing guidance. A total of 910 patients were enrolled and 873 were included in the efficacy analysis; group sizes in the efficacy analysis were 214 (10 mg), 223 (30 mg), 222 (60 mg), and 214 (placebo) ^[1]. The NDA and approval materials are documented in the FDA files and the current label and highlights ^[1]^[2]^[3]^[4].

FAQ

Q1 What is atogepant (Qulipta) approved for?

Atogepant (Qulipta) is approved by the FDA for the preventive treatment of migraine in adults. The approval was based on phase 3 randomized trial data from the ADVANCE study demonstrating reductions in monthly migraine days versus placebo across once‑daily doses.

Q2 How does atogepant work?

Atogepant is an oral small‑molecule calcitonin gene‑related peptide (CGRP) receptor antagonist. It blocks the CGRP receptor, a target implicated in migraine pathophysiology; this mechanism is cited in the prescribing information and clinical literature supporting the drug’s preventive effects in migraine.

Q3 What is the recommended dosing for episodic migraine?

For episodic migraine the approved recommended doses are 10 mg, 30 mg, or 60 mg taken once daily, with the choice of dose guided by efficacy, tolerability, comedications, and renal function. The label includes dose modification recommendations for strong CYP3A4 inhibitors, CYP3A4 inducers, OATP inhibitors, and for patients with severe renal impairment or end‑stage renal disease; for example, strong CYP3A4 inhibitors warrant a 10 mg once‑daily dose for episodic migraine. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects clinicians should watch for?

In the ADVANCE trial the most common adverse events with atogepant were constipation (6.9% to 7.7% across doses) and nausea (4.4% to 6.1% across doses). The approved label also lists fatigue/somnolence among common reactions and notes hypersensitivity reactions including anaphylaxis and other immune‑mediated events reported postmarketing. Liver enzyme elevations occurred in the development program but the rates of transaminase elevations >3 times the upper limit of normal were reported as 0.9% with atogepant versus 1.2% with placebo; cases linked temporally to treatment were asymptomatic and resolved within 8 weeks after discontinuation in the controlled program. Postmarketing reports include new or worsened hypertension and Raynaud’s phenomenon with CGRP antagonists; the label provides monitoring and discontinuation guidance.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Atogepant for Episodic Migraine: 1.7‑Day MMD Drop (ADVANCE)

FDA Approves Atogepant for Episodic Migraine: 1.7‑Day MMD Drop (ADVANCE)

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Neurology in your inbox.

Related Clinical Updates

Oveporexton: Increases Wakefulness (MWT) 25.4 min in Narcolepsy Type 1

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency

lecanemab and donanemab: amyloid confirmation and PET criteria for patient selection

Verified HCP Portal